MEDINDIA
English
हिन्दी
Español
français
中文
Email
abobotulinumtoxinA
Pirenzepine may increase the anticholinergic activities of Botulinum Toxin Type A.
Aclidinium
Pirenzepine may increase the anticholinergic activities of Aclidinium.
Alfentanil
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Alfentanil.
Alphaprodine
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Alphaprodine.
Ambenonium
The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Ambenonium.
AMBROXOL ACEFYLLINATE
The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Ambroxol acefyllinate.
Ambroxol-Theophylline-7-Acetate
The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Ambroxol acefyllinate.
Aminophylline
The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Aminophylline.
Atracurium
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Atracurium.
Atracurium Besylate
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Atracurium besylate.
Atropine
The risk or severity of adverse effects can be increased when Atropine is combined with Pirenzepine.
Benactyzine
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Benactyzine.
Bendroflumethiazide
The serum concentration of Bendroflumethiazide can be increased when it is combined with Pirenzepine.
Benztropine
The risk or severity of adverse effects can be increased when Benzatropine is combined with Pirenzepine.
Biperiden
The risk or severity of adverse effects can be increased when Biperiden is combined with Pirenzepine.
Botulinum Toxin Type A
Pirenzepine may increase the anticholinergic activities of Botulinum Toxin Type A.
Buprenorphine
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Buprenorphine.
Butorphanol
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Butorphanol.
Butylscopolamine
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Butylscopolamine.
Chlorothiazide
The serum concentration of Chlorothiazide can be increased when it is combined with Pirenzepine.
Chlorphenoxamine
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Chlorphenoxamine.
Chlorthalidone
The serum concentration of Chlorthalidone can be increased when it is combined with Pirenzepine.
Clozapine
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Clozapine.
Codeine
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Codeine.
Codeine Anhydrous
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Codeine.
CODEINE POLISTIREX
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Codeine.
Cyclopenthiazide
The serum concentration of Cyclopenthiazide can be increased when it is combined with Pirenzepine.
Cyclopentolate
The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Pirenzepine.
Darifenacin
The risk or severity of adverse effects can be increased when Darifenacin is combined with Pirenzepine.
Demecarium
The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Demecarium.
Desloratadine
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Desloratadine.
Dexetimide
The risk or severity of adverse effects can be increased when Dexetimide is combined with Pirenzepine.
Dextromoramide
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Dextromoramide.
Dezocine
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Dezocine.
Dicyclomine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Pirenzepine.
Dihydrocodeine
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Dihydrocodeine.
Diphenoxylate
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Diphenoxylate.
Distigmine
The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Distigmine.
Donepezil
The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Donepezil.
Dyphylline
The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Dyphylline.
Echothiophate
The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Echothiophate.
Edrophonium
The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Edrophonium.
Eluxadoline
Pirenzepine may increase the constipating activities of Eluxadoline.
Ethylmorphine
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Ethylmorphine.
Fentanyl
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Fentanyl.
Fesoterodine
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Fesoterodine.
Fosphenytoin
The serum concentration of Fosphenytoin can be increased when it is combined with Pirenzepine.
Galantamine
The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Galantamine.
Gallamine Triethiodide
The risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Pirenzepine.
Ginkgo biloba extract
The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Ginkgo biloba.
Glucagon
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Glucagon recombinant.
glucagon (rDNA)
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Glucagon recombinant.
Glycopyrronium
Pirenzepine may increase the anticholinergic activities of Glycopyrronium.
Heroin
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Heroin.
Homatropine
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Homatropine.
Human Secretin
The therapeutic efficacy of Human secretin can be decreased when used in combination with Pirenzepine.
Hyaluronidase
The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Hyaluronidase.
Hyaluronidase, Ovine
The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Hyaluronidase.
Hydrochlorothiazide
The serum concentration of Hydrochlorothiazide can be increased when it is combined with Pirenzepine.
Hydrocodone
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Hydrocodone.
HYDROCODONE POLISTIREX
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Hydrocodone.
Hydroflumethiazide
The serum concentration of Hydroflumethiazide can be increased when it is combined with Pirenzepine.
Hydromorphone
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Hydromorphone.
Hyoscyamine
The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Pirenzepine.
incobotulinumtoxinA
Pirenzepine may increase the anticholinergic activities of Botulinum Toxin Type A.
Indapamide
The serum concentration of Indapamide can be increased when it is combined with Pirenzepine.
Ipratropium Bromide
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pirenzepine.
Ipratropium Bromide Anhydrous
The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pirenzepine.
Isoflurophate
The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Isoflurophate.
Levomethadyl
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Levomethadyl Acetate.
Levorphanol
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Levorphanol.
Malathion
The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Malathion.
Mecamylamine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Pirenzepine.
Mefloquine
The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Mefloquine.
Memantine
The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Memantine.
Meperidine
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Pethidine.
Methadone
Pirenzepine may increase the central nervous system depressant (CNS depressant) activities of Methadone.
Methadyl Acetate
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Methadyl Acetate.
Methantheline
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Methantheline.
Methixene
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Metixene.
Methscopolamine
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Methscopolamine.
Methscopolamine Bromide
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Methylscopolamine bromide.
Methyclothiazide
The serum concentration of Methyclothiazide can be increased when it is combined with Pirenzepine.
Metoclopramide
The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Metoclopramide.
Metolazone
The serum concentration of Metolazone can be increased when it is combined with Pirenzepine.
Mianserin
Mianserin may increase the anticholinergic activities of Pirenzepine.
Minaprine
The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Minaprine.
Mirabegron
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Mirabegron.
Morphine
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Morphine.
Nabilone
Pirenzepine may increase the tachycardic activities of Nabilone.
Nalbuphine
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Nalbuphine.
Neostigmine
The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Neostigmine.
Normethadone
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Normethadone.
O-PHENANTHROLINE
The therapeutic efficacy of Pirenzepine can be decreased when used in combination with 1,10-Phenanthroline.
Octotropine Methylbromide
The risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Pirenzepine.
Octylonium
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Otilonium.
Olanzapine
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Olanzapine.
onabotulinumtoxinA
Pirenzepine may increase the anticholinergic activities of Botulinum Toxin Type A.
Opium
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Opium.
Orphenadrine
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Orphenadrine.
Oxitropium
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Oxitropium.
Oxybutynin
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Oxybutynin.
Oxycodone
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Oxycodone.
Oxymorphone
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Oxymorphone.
Oxyphenonium
The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Pirenzepine.
Pancuronium
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Pancuronium.
Pancuronium Bromide
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Pancuronium.
Paregoric
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Morphine.
Pentazocine
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Pentazocine.
Phenytoin
The serum concentration of Phenytoin can be increased when it is combined with Pirenzepine.
Physostigmine
The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Physostigmine.
Pipecuronium
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Pipecuronium.
Pirinitramide
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Piritramide.
Polythiazide
The serum concentration of Polythiazide can be increased when it is combined with Pirenzepine.
Potassium Chloride
Pirenzepine may increase the ulcerogenic activities of Potassium Chloride.
Pramlintide
Pramlintide may increase the anticholinergic activities of Pirenzepine.
Procyclidine
The risk or severity of adverse effects can be increased when Procyclidine is combined with Pirenzepine.
Profenamine
The risk or severity of adverse effects can be increased when Ethopropazine is combined with Pirenzepine.
Propantheline
The risk or severity of adverse effects can be increased when Propantheline is combined with Pirenzepine.
Propantheline Bromide
The risk or severity of adverse effects can be increased when Propantheline is combined with Pirenzepine.
Propiverine
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Propiverine.
Propoxyphene
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Dextropropoxyphene.
Pyridostigmine
The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Pyridostigmine.
Pyridostigmine Bromide
The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Pyridostigmine.
Quinethazone
The serum concentration of Quinethazone can be increased when it is combined with Pirenzepine.
Quinidine
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Quinidine.
Remifentanil
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Remifentanil.
rimabotulinumtoxinB
Pirenzepine may increase the anticholinergic activities of Botulinum Toxin Type B.
Rivastigmine
The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Rivastigmine.
Scopolamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Pirenzepine.
Scopolamine Hydrobromide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Pirenzepine.
Secretin
The therapeutic efficacy of Secretin can be decreased when used in combination with Pirenzepine.
Sodium Oxybate
Pirenzepine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Solifenacin
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Solifenacin.
Sufentanil
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Sufentanil.
Sulpiride
Pirenzepine may increase the anticholinergic activities of Sulpiride.
Tacrine
The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Tacrine.
Tapentadol
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Tapentadol.
Teduglutide
The serum concentration of Pirenzepine can be increased when it is combined with Teduglutide.
Tetrahydrocannabinol
Pirenzepine may increase the tachycardic activities of Dronabinol.
Theophylline
The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Theophylline.
Theophylline anhydrous
The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Theophylline.
Tiotropium
Pirenzepine may increase the anticholinergic activities of Tiotropium.
Tolterodine
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Tolterodine.
Topiramate
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Topiramate.
Tramadol
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Tramadol.
Trichlormethiazide
The serum concentration of Trichlormethiazide can be increased when it is combined with Pirenzepine.
Trihexyphenidyl
The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Pirenzepine.
Trihexyphenidyl Hydrochloride
The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Pirenzepine.
Trimethaphan
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Trimethaphan.
Tropicamide
The risk or severity of adverse effects can be increased when Tropicamide is combined with Pirenzepine.
Trospium
The risk or severity of adverse effects can be increased when Trospium is combined with Pirenzepine.
Tubocurarine
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Tubocurarine.
Umeclidinium
Pirenzepine may increase the anticholinergic activities of Umeclidinium.
Vecuronium
The risk or severity of adverse effects can be increased when Pirenzepine is combined with Vecuronium.
